



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48, 51/08, C07K 19/00	A1	(11) International Publication Number: WO 98/16254 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/17924 (22) International Filing Date: 14 October 1997 (14.10.97) (30) Priority Data: 60/028,430 17 October 1996 (17.10.96) US (71) Applicant (for all designated States except US): IMMUNOMEDICS, INC. [US/US]; 300 American Road, Morris Plains, NJ 07950 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): GOLDENBERG, David, M. [US/US]; 30 Pleasant Valley Road, Mendham, NJ 07945 (US). (74) Agents: SAXE, Bernhard, D. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NON-ANTIGENIC TOXIN-CONJUGATE AND FUSION PROTEIN OF INTERNALIZING RECEPTOR SYSTEM (57) Abstract A conjugate of a toxin and a cytokine, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , each optionally further comprising a radionuclide, are useful therapeutic reagents for treating leukemias and lymphomas.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NON-ANTIGENIC TOXIN-CONJUGATE AND FUSION PROTEIN OF INTERNALIZING RECEPTOR SYSTEM

Background of the Invention

5 The present invention relates to a fusion protein of a component of an internalizing receptor system and a moiety that binds to a specific cellular surface marker on a cell, to a conjugate of a toxin and a ligand for the internalizing receptor system, and to a method of tumor therapy using the conjugate and internalizing receptor system.

10 There is now a fairly large and growing body of experience in the use of monoclonal antibodies (mAbs) for the therapy of lymphoma. Several studies targeting different B-cell restricted CD (clusters of differentiation) antigens have shown promising results. These studies have used radiolabeled mAbs and, to a lesser extent, mAb-toxin conjugates, and have targeted CD19-22, CD37, and
15 HLA-DR.

 MAbs used in lymphoma therapy differ in their ability to bind cognate antigen and to become internalized. For example, CD22 exhibits efficient internalization as well as reexpression of antigen after internalization. It suffers, however, from relatively low expression levels on most B-cell malignancies, and
20 is not widely expressed, *e.g.*, it is expressed on only 30-50% of cases of B-cell lymphocytic leukemia (B-CLL).

 The present inventor has studied an anti-CD22 mAb, LL2. Preliminary studies using LL2 labeled with ¹³¹I for both therapy and imaging of NHL have produced response rates of 30-90+ %, with varying percentages of complete
25 responses and differences in durability of response. Higher response rates and longer disease-free survival have been associated with higher total doses of antibody and of radioactivity, which usually have required autologous bone marrow or peripheral stem cell rescue. While the results are encouraging, it is desired to increase therapeutic efficacy and decrease toxicity, particularly
30 myelotoxicity.

 The CD20 antigen, in contrast to the CD22 antigen, is a quite highly expressed B-cell restricted antigen that is expressed on a wide range of B-cell

5 malignancies, ranging from acute lymphocytic leukemia (ALL) to the more differentiated B-Cell (B-CLL) and non-Hodgkin's lymphoma (NHL), and even to hairy cell leukemia (HCL). It generally is expressed on cells in the vast majority of cases of these malignancies at a high antigen density. A major disadvantage of CD20 is that it is a slowly internalizing antigen. For RAIT directed against CD20 this feature may not be a problem, but it militates significantly against the use of CD20 for toxin-based therapy.

10 A further problem of CD20 is the fact that B-cell malignancies exhibit a more rapid dissociation of bound anti-CD20 mAbs from the surface as compared to nonlymphoma tumor cells. This suggests that a therapy that uses bonding to a B-cell restricted antigen, particularly those characterized by slow internalization, would not be successful.

15 A variety of mAb-toxin constructs have been tested in both *in vitro* experiments and human trials. These studies have demonstrated potent and specific effects of these reagents. Most of the toxin molecules that have been used derive from either plant or bacterial sources and hence produce allergenic sensitization in patients. This severely limits the duration of therapy.

20 While major progress has been made in the therapy of B-cell malignancies such as NHL and B-CLL, there remain a substantial number of patients with B-cell malignancies who exhibit primary resistance to, or relapse after, optimal chemotherapy. A therapy that is effective over long periods of time in most or all patients with B-cell malignancies is desired.

Summary of the Invention

25 It is therefore an object of the present invention to provide a more effective and less toxic anti-tumor therapy, particularly a therapy for treatment of B-cell malignancies, such as NHL and B-CLL.

It is another object of the invention to improve the value as antigenic targets of slowly internalizing surface antigens such as the CD20 antigen.

It is a further object of the invention to overcome the tendency of antibodies bound to the surface of lymphoma cells to dissociate rapidly from the surface of the cells.

It is yet another object of the present invention to use B-cell restricted
5 antigens, particularly the CD20 antigen, in anti-tumor therapy.

These and other objects of the invention are achieved by providing a conjugate of toxin or therapeutic radionuclide and IL-15, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , each
10 optionally further comprising a diagnostic radionuclide, which are useful therapeutic reagents for treating leukemias and lymphomas.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating
15 preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Detailed Description of the Preferred Embodiments

20 It has been discovered, surprisingly, that the value of surface antigens as antigenic targets can be improved significantly by functionally linking them to a high affinity, internalizing receptor system. The present invention is of particular advantage in the case of surface antigens that do not internalize or that internalize slowly. A preferred example of a high affinity, internalizing receptor system is
25 the IL-15 receptor system. When the IL-15 receptor system is used, it can be employed with all malignant cells that contain the β/γ_c chains of IL-15 receptor. The presence of β/γ_c chains of IL-15 on the cells provides the basis for a continuously internalizing receptor system that can be bridged to a surface antigen, particularly a slowly internalizing antigen, by way of a bispecific fusion
30 protein and cognate ligand. The method according to the invention results in

increased intracellular delivery into the malignant cell of cytotoxic ligands. It also improves methodologies in which a radionuclide is used as a therapeutic agent, by producing a tighter binding of the radionuclide to the malignant cell and by reducing dissociation of the targeting agent from the cell surface.

5 In accordance with the invention, malignant cells are pretargeted with a fusion protein. The fusion protein comprises a region of IL-15 α , preferably an extracellular domain, and a bispecific antibody or antibody fragment that has a first specificity for a cell marker specific to a malignant cell marker and a second specificity for the region of IL-15 α . The fusion protein is positioned on the
10 malignant cells by means of the surface antigen expressed by the malignant cells. In an alternative embodiment, the fusion protein is formed *in situ*, by first administering the bispecific antibody, and then administering IL-15 α which binds to the bispecific antibody that is already bound to the malignant cells. In either case, addition of an armed ligand comprising IL-15 ligand armed with a toxin or
15 with a radionuclide then results in the formation of a trimeric complex of the β/γ_c chains of IL-15 receptor, in which the α -chain of IL-15 receptor attached to the surface antigen and IL-15/toxin and/or radionuclide conjugate. Alternatively, both the fusion and the trimeric complex can be formed *in situ*. This leads to rapid internalization of toxin and/or radionuclide into the malignant cells. While
20 internalization is not necessary for a therapeutic radionuclide to be effective, the trimeric complex provides a tighter binding to the malignant cells, and thus improves these modalities as well.

Receptor complexes for both IL-2 and IL-15 have three primary chains. The β and γ_c chains are common to the two receptors, and there are individual,
25 private alpha chains, IL-2R α and IL-15R α . The IL-2/IL-2 receptor system consists of at least three subunits, IL-2R α , IL-2R β and IL-2R γ_c . This multi-subunit receptor is capable of binding ligand with high affinity and the ligand/receptor complex is rapidly internalized ($t_{1/2} \approx 15$ min). IL-2R α when expressed in the absence of the other two chains internalizes slowly, and is unable
30 to transduce a signal when expressed by itself. When IL-2R α is juxtaposed to the other subunits by the presence of ligand the entire ligand/ $\alpha\beta\gamma$ complex

internalizes at the rapid rate intrinsic to the IL-2R β/γ_c dimer. IL-2R α thus raises the affinity of the β/γ_c complex from $K_a \approx 10^9$ to $\approx 10^{11} \text{ M}^{-1}$.

IL-15R α is structurally similar to IL-2R α , and is of similar size. As compared to IL-2R α , IL-15R α has an affinity for its cognate ligand ($K_a \geq 10^{10} \text{ M}^{-1}$) that is at least two orders of magnitude greater than that of IL-2R α for its ligand. IL-15R α , like IL-2R α , has a short intracytoplasmic domain and is unable to transduce a signal when expressed by itself. Thus, the IL-15/IL-15R system operates in a similar fashion to the IL-2/IL-2R system and will internalize all three of its receptor components.

The antigen to which the fusion protein containing the IL-15 α is anchored is one that is specific to the malignant cell type. In a preferred embodiment, the antigen is a high-density B-cell restricted antigen. As shown herein, there is expression in malignant B-cells of the β and γ_c chains of IL-15 receptor, and little or no expression of the receptor. The presence of β/γ_c chains of IL-15 receptor on malignant B-cells forms the basis for a continuously internalizing receptor system that can be used in conjunction with B-cell restricted antigens specifically to introduce toxin, and optionally radionuclides, into malignant B-cells. This system can be self-amplifying in that internalized receptors can be either recycled or resynthesized and expressed.

For treatment of NHL, B-CLL, HCL and ALL, the high-density CD20 antigen is a particularly suitable surface antigen. For ALL or multiple myeloma, CD38 is suitable, while for acute myelogenous leukemia (AML) or chronic myelogenous leukemia (CML), the CD15 antigen can be used. In addition a variety of solid tumor surface antigens have been described, and any of these can be used in accordance with the present invention.

A bispecific antibody-based molecule, preferably a Mab, is used as the vehicle to position the α -chain of the IL-15 receptor on the surface of the targeted cells. Positioning large amounts of IL-15R α on cells that already express the β/γ_c chains of IL-15 receptor will, after addition of armed IL-15 ligand, induce internalization of this ligand/receptor complex by interaction with the β and γ_c chains of IL-15 receptor already present on the cells.

Murine Mab frequently induce human-anti-mouse antibodies (HAMA). When such Mab are used in the present invention, this problem of immunogenicity is minimized by genetically engineering the murine Mab using either chimerization or humanization. Both strategies involve the replacement of some part of the murine sequences with human immunoglobulin sequences. In the chimeric approach the constant regions are replaced with corresponding human sequences. With humanization there is additional replacement of framework sequences within the variable regions of the heavy and light chain genes. Both of these approaches have, in fact, resulted in Mabs with lower immunogenicity. For example, the LL2 antibody has been humanized with retention of its native ability to bind antigen and become internalized, as disclosed in copending application Serial No. 08/289,576, which is incorporated herein by reference in its entirety.

Mab engineering techniques have been used to produce another class of antibody molecule, namely the single chain antibody, scF_v. This molecule is produced by cloning the V_H and V_L segments from the Mab of interest and splicing them together with a short linker region interposed between them. These molecules, after proper design and renaturation, retain the antigen binding activity of the parent Mab and can be expressed at high levels in *E. coli*-based expression systems. These constructs then can provide a platform for the engineering of bifunctional single chain molecules that can link a second antigenic target to the first to retarget effector cells or molecules.

The invention utilizes pretargeting of the antigenic target with the fusion protein comprising the Mab or Fc fragments connected to a region of IL-15R α . In this approach, enhanced tumor/normal tissue ratios of the Mab or Fc fragment are achieved by giving the nontoxic first reagent that has reactivity to the antigenic target. This is followed by a tumor targeting/washout interval that allows for uptake by tumor masses of this first agent and its clearance from normal tissues, after which the toxic conjugate is given.

Prior to the pretargeting with the fusion protein containing the region of IL-15 α , the cells may be pretargeted with streptavidin-conjugated antibodies or biotinylated antibodies in conjunction with avidin and biotin. For example,

biotinylated anti-CD20 antibodies can be administered, followed by administration of avidin to provide additional binding sites. Subsequently administered biotinylated IL-15R α then attaches to the avidin sites.

Both two-step and three-step methods that utilize avidin-biotin chemistry can be employed. These generally involve, depending on the specific protocol, the administration of either avidin- or biotin-conjugated-mAb. This is followed, after an interval of 1-3 days, by the injection of biotin or avidin that is labeled with either a gamma-emitting radionuclide for imaging or by a beta or alpha emitter for therapy. The three-step method interposes a clearing step between the pretargeting and targeting steps. This step promotes the clearance of circulating, residual pretargeting agent, thereby reducing this pool and subsequent access to it by the targeting agent. In this system avidin is given to promote clearance since its elimination kinetics show a very rapid initial phase with a $t_{1/2}=1$ min which accounts for the majority of the total and a second phase with a $t_{1/2}\approx 30$ min.

The methods that use biotin and avidin lead to an increased number of sites for binding of active conjugate, but these improvements are mitigated by the fact that both avidin and the alternate protein, streptavidin, are immunogenic. Somewhat less than 30% of patients develop antibodies to avidin and a full 70% of patients develop antibodies to streptavidin. Accordingly, it is less preferable to use a pretargeting with biotin/avidin.

In a preferred embodiment according to the invention, therefore, a two-step procedure is used in which only the fusion protein containing the region of IL-15 α fusion protein, in its optimal humanized form, is used to pretarget the malignant cells. The fusion protein according to the present invention has low immunogenic potential. The pretargeting agent bears human IL-15R α , which has a high affinity for ligand. This fusion protein, owing to its relatively low molecular weight (70 kDa vs. 150 kDa for intact IgG), has the potential for greater penetration into the interior of tumors.

The second step reagent, the IL-15 construct, likewise has low immunogenic potential and a low molecular weight (rIL-15 from *E. coli* has a MW of 13 kDa) to aid in both tumor penetration and clearance from non-tumor

sites. It is administered after the pretargeting, IL-15R α fusion protein has localized on the malignant cells and substantially cleared from the circulation. This system could also be adapted to include a third step if this were necessary, *i.e.*, an intervening preclearance. This can be done by galactosylating the IL-15
5 ligand. For higher galactose substitution IL-15 can be crosslinked covalently to asialofetuin.

The IL-15 ligand can be armed with a radionuclide or a toxin. The radionuclide can be either a diagnostic or therapeutic radionuclide. In a preferred embodiment, the IL-15 ligand is used to administer both radionuclide and toxin.
10 The same IL-15 ligand can be armed with both radionuclide and toxin, or separate IL-15 ligands can be armed with radionuclide and toxin. Where separate IL-15 ligands armed with radionuclide and toxin are used, these may be administered together or sequentially.

When the IL-15 ligand is armed with a toxin, a preferred toxin is a
15 ribonuclease, such as onconase. Onconase is a non-mammalian RNase purified from *Rana pipiens* oocytes. It has been shown in clinical trials to have anti-tumor activity against human pancreatic cancer, but has been found to have minimal anti-tumor activity against B-cell malignancies such as B-cell lymphocytic leukemia.

20 The fusion protein and armed ligand conjugate are administered in a composition with a pharmaceutically acceptable carrier. In this regard, a pharmaceutically acceptable carrier is a material that can be used as a vehicle for administering the fusion protein or armed ligand because the material is inert or otherwise medically acceptable, as well as compatible with the fusion protein or
25 armed ligand.

Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. For example, since the β/γ_c chains of IL-15 receptor are the same as the β/γ_c chains of IL-2 receptor, the fusion protein can be used to introduce
30 IL-2R α onto the malignant cells, followed by administration of an RNase-IL-2 conjugate. Moreover, fusion proteins of either IL-15R α or IL-2R α can be made in which the fusion partner is an antibody other than an anti-CD20 antibody. This

enables pretargeting of any tumor that carries a specific marker. Many antibodies and antibody fragments which specifically bind markers produced by or associated with tumors or infectious lesions have been disclosed, *inter alia*, in Hansen *et al.* U.S. Patent 3,927,193 and Goldenberg U.S. Patents 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,460,459 and 4,460,561. Where the tumor additionally contains the β/γ_c chains of IL-15/IL-2 receptors, the fusion protein will be rapidly internalized.

The following examples are illustrative of the present invention, but are not to be construed as limiting.

Example 1. Determining of expression of the β/γ_c chains of IL-2/IL-15 by a malignant cell type

Five B-lymphoma cell lines were assayed for IL-15 and IL-2 binding, along with two non-B cell lines (MLA 144, a T cell line known to express IL-2R β / γ_c and MB-02, an AML derived cell line). ¹²⁵I-labeled rIL-15 was used. Cold ligand inhibition was done with both IL-2 and IL-15 to allow estimation of the contribution of IL-15R α to the overall binding.

Washed cells (2×10^6) were suspended in binding buffer (growth medium). To these tubes was added either buffer or a 150-fold molar excess of cold rIL-15 or a 500-fold excess of cold rIL-2 for 15 min @ 4°C . Then ^{125}I -IL-15 was added at 1.5 nM final concentration. Binding was allowed to proceed for 90 min @ 4°C after which cells were transferred to 0.4 ml tubes and spun through a cushion of 80/20 dibutyl phthalate/olive oil. The tips were then cut off and counted in a gamma counter. The results are shown in Table 1.

TABLE 1

CELL LINE	CPM ^{125}I -IL-15 BOUND PER 2×10^6 CELLS WITH NO ADDITION - NONSPECIFIC	CPM ^{125}I -IL-15 BOUND PER 2×10^6 CELLS + 500X EXCESS rIL-2 - NONSPEC.
MLA 144	708	310
MB-02	502	448
DHL-6	69	0
DAUDI	105	48
RAJI	634	303
RAMOS	48	19
RL	371	117

10 All the B-lymphoma lines tested showed a low but consistent specific
 binding of labeled IL-15, that was inhibited by cold IL-15. IL-2 competes with
 IL-15 for binding to IL-2R β / γ_c , but not with IL-15 binding to IL-15R α . Similar
 degrees of inhibition by both unlabeled ligands suggest a preponderance of the β
 and γ chains over IL-15R α , *i.e.*, most of the binding in the cells was through the
 15 IL-2R β / γ_c dimer. Estimates based on cpm bound under saturating conditions
 along with degrees of iodine substitution derived from specific activity
 measurements showed that IL-15 receptor numbers on these cells was in the range
 of 50- 500 sites/cell. This is similar in amount to the number of IL-2R β / γ_c sites
 that has previously been observed on B-CLL and NHL cells. The presence of
 20 β / γ , even in low numbers, allows for the possibility of a continuously
 internalizing receptor system that can be bridged to cell marker antigen by way
 of a bispecific fusion protein and cognate ligand.

Example 2. Assessment of toxins for effectiveness against B-cell malignancies

25 Three different mAbs, LL1, a class II invariant chain, LL2, an anti-CD22
 antibody, and 5E9, an anti-transferrin receptor antibody, were conjugated to two
 RNase superfamily toxins, onconase and EDN. The resulting conjugates were

tested on a panel of cell lines that included three B-lymphoma cell lines, Daudi, Raji, CA-46, a breast cancer line, MDA-MB-231, and a human T cell line, HuT 102. The results showed that LL2-onconase had the lowest IC₅₀ values of all the conjugates tested. Toxicity of onconase-based immunotoxins on B lymphoma cell line, Daudi, was further demonstrated with conjugates of onconase and LL2. LL2 is an antibody to CD22, an efficiently internalizing antigen. Both whole IgG and Fab' conjugates were prepared and were found to inhibit this cell line in the subnanomolar range. The effect was shown to be dependent on the CD22 reactivity of the conjugate, since inhibitory effects are nearly eliminated by excess cold antibody.

Example 3. Construction of a soluble IL-15R α -1F5scF_v fusion protein

The hybridoma 1F5, IgG_{2a} κ is available from the American Type Culture Collection in Rockville, MD. This hybridoma is used to produce mAb both by growth of the hybridoma in tissue culture and/or ascites with subsequent purification on protein A-agarose. It is cultured in RPMI 1640 supplemented with 2mM L-glutamine and 50 μ g/ml each of penicillin and streptomycin and 10% FCS.

For isolation of the V_H and V_L genes of 1F5, 3 x 10⁷ cells are used for isolation of total RNA. This is done by solubilizing washed cell pellets in Trizol reagent (Gibco/BRL, Grand Island, NY) followed by RNA isolation via the acid-guanidium phenol-chloroform method. Five μ g of total RNA are used as template for production of 1st strand cDNA using the AMV reverse transcriptase-based kit of Boehringer-Mannheim (Indianapolis, IN). From 2 to 5% of the resulting reaction products is used as a template for PCR amplification of the V_H and the V_L genes.

Universal primers, as described by Orlandi *et al.* (1989), are used in the PCR reactions. These primers are VH1FOR and VH1BACK for V_H and VK1FOR and VKBACK1 for the kappa V_L. Alternatively, primers described by Leung *et al.* (1993) used successfully in chimerization and humanization of the LL2 and MN14 mAbs are used. Standard PCR conditions with 0.5 μ M primers, 1.5 U *Taq* polymerase, 0.25 mM dNTPs, 2 mM MgCl₂ in the routine

TrisHCl/KCl/gelatin buffer are used. PCR is carried out for 30 cycles with an initial denaturation for 4 min at 92°C, with cycles consisting of annealing @ 50°C for 45 seconds, polymerization at 72°C for 45 seconds and subsequent denaturation at 94°C for 30 seconds.

5 Aliquots of the PCR products are analyzed on an ethidium bromide-stained 2% agarose gel. Appropriate PCR-amplified fragments are isolated on a 2% low-melt agarose gel and stained with ethidium bromide. Fragments are excised, the gel piece is melted and digested with β -agarase and then precipitated with ethanol. Aliquots of the gel purified material are cloned into the TA cloning vector pCRII
10 (Invitrogen, San Diego), transformed into the recA- strain, XL1Blue (Invitrogen) and sequenced by standard dideoxy methodology with ³⁵S-labeled precursor.

The construct uses a linker that is effective in multiple single chain F_v antibodies (scF_v), the amino acid sequence (GGGGS)₃ to which is added three amino acids from the light chain elbow region to improve solubility and stabilize
15 the monomeric form of the F_v. After inspecting the V_H and V_L sequences for restriction sites, oligonucleotides with an *Eco*RI, or appropriate alternate enzyme, overhang spanning the requisite 54 bp of the linker sequence are synthesized and allowed to anneal. This oligonucleotide is then ligated to the *Eco*RI-excised and gel-purified V_H fragment by T4 DNA ligase. The V_L fragment is excised and
20 purified in the same fashion and then ligated to the V_H-linker fragment.

The 1F5scF_v is religated into pCRII plasmid and transformed into bacteria and sequenced. The validated scf_v sequence is ligated to an extracellular region of IL-15R α . After the sequence is verified, the two binding regions of the fusion molecule are tested in binding assays. For situations where the F_v moiety does
25 not have adequate antigen binding activity, an additional F_v is designed with the V_L situated 5' to the V_H with the same linker sequence.

PCR primers are selected based on the published nucleotide sequence of hIL-15R α , starting at the NH₂-terminus of the mature protein on one strand and delimited on the opposite strand by the immediate extracellular juxtamembrane
30 region, excluding the transmembrane and intracytoplasmic regions. The primers include adapter sequences to allow for sequential restriction digestion with *Eco*RI and *Nco*I for compatibility with the bacterial expression vector. RT-PCR

amplification of IL-15R α is carried out on total RNA from a cell line with high expression of IL-15R α , such as HuT 102B2. Correct size fragments are cloned into the pCRII plasmid and sequenced, as described above. Sequence-validated fragments are then digested with *EcoRI* plus *NcoI* and ligated to the 1F5scF_v fragment. The resulting orientation is shown below.



The juxtamembrane region of sIL-15R α is selected as a linker since, by analogy to IL-2R α , the IL-15 binding region is predicted to be near the NH₂-terminus. In addition, several truncated forms of IL-15R α have been shown to bind IL-15 as well as the full length, wild-type form. In order to obtain optimal binding, truncations of the sequence are tested.

The fusion sequence then is ligated into the pET21d vector (Novagen, Madison, WI) and transformed into the XL1Blue host. Bacterial clones are picked and sequenced using T7 and Sp6 primers in combination with internal specific primers. Clones with authentic sequences are expanded, and plasmids are isolated and transformed into the AD494(DE3) *E. coli* expression host. This host strain carries mutations in the thioredoxin reductase gene, thereby creating relatively oxidizing conditions that promote disulfide bond formation (Novagen).

Example 4. Expression of sIL-15R α -1F5scF_v fusion protein

Transformed colonies are picked and expanded in LB broth to an OD₆₀₀ \approx 0.5. They then are induced to express protein with 0.4 mM IPTG for 3 to 6 hours at 37°C. Bacterial cells from a small scale culture are pelleted and lysed with SDS-PAGE sample buffer, the debris is removed by centrifugation and an aliquot is loaded on a 10% SDS-PAGE gel. Part of the gel is cut off and stained with Coomassie Blue and the remainder is transblotted to an Immobilon-P membrane. This membrane then is stained with either a nickel-alkaline phosphatase conjugate (Qiagen, Chatsworth, CA), which recognizes the hexahistidine tag, or goat-anti-mouse-alkaline phosphatase (Kirkegaard and Perry,

Gaithersburg, MD), to detect immunoglobulin sequences. The blot is developed with the ECL substrate, CSPD, and exposed to photographic film.

Once good production is confirmed, expression cultures are scaled up. Initial scale-up is to cultures of ~1 liter. Bacterial cells are pelleted and washed
5 in 300 mM NaCl/50 mM TrisHCl, pH=8.0, then resuspended in the same buffer and treated with 0.5 mg/ml lysozyme for 20 minutes on ice. The suspension is then sonicated on ice with three 30 second bursts. The insoluble material then is pelleted at 14,000 x g for 5 minutes. The inclusion-body containing pellet is washed once with 50 mM TrisHCl, pH=8.0/200 mM NaCl/0.2% Triton X-100.

10 Solubilization and renaturation are performed according to an adapted version of the method of Kurucz *et al.* (1995), used with a bispecific scF_v that is a fusion of two individual scF_vs. Briefly, the washed inclusion body preparation is solubilized with a buffer containing 2% sodium lauroylsarcosine/50 mM TrisHCl, pH=9.0 at a protein concentration of ~2 mg wet weight/ml. CuSO₄
15 is added at 50 μM and the mixture is allowed to oxidize in air at room temperature for 24 hours. Insoluble material is pelleted and the material is absorbed in batch mode to Ni²⁺-IDA resin (Talon™, Clontech, Palo Alto, CA) for 20 minutes at room temperature, based on the binding capacity of the resin.

Total protein concentrations is determined by a modified Bradford assay
20 (Coomassie Plus™, Pierce, Rockford, IL) in the low level mode with buffer blanks. In the case of detergent interference, a detergent insensitive assay using bicinchoninic acid is used. With this detergent, A₂₈₀ estimates can be made. After adsorption the resin is transferred to a column and washed with 20 column volumes of the solubilizing buffer followed by ≥ 20 column volumes, or until
25 A₂₈₀ < 0.02, with 8M urea/50 mM MES, pH=6.0. Bound product is eluted in 8M urea/300 mM imidazole/TrisHCl, pH=7.4. All fractions are saved and analyzed by SDS-PAGE with Coomassie staining. Fractions of sufficient purity then are dialyzed versus 0.4 M arginine/50 μM CuSO₄/50 mM TrisHCl, pH=8.0.

Example 5. Assay of antigen binding activity of sIL-15R α -1F5scF_v fusion protein

Antigen binding activity of the fusion protein is assayed by radiolabeling it with ¹²⁵I by the Iodogen method such that specific activity does not exceed 20 μ Ci/ μ g. Panels of human cell lines that are known to be positive or negative for CD20 are tested in a standard binding assay in the presence and absence of cold 1F5, cold fusion protein and cold IL-15. Binding occurs through the anti-CD20 moiety. After 1 hour on ice the cells are spun through a cushion of 80/20, dibutyl phthalate/olive oil and the tips of the tubes are cut off and counted in a gamma counter.

To test for IL-15 binding capacity a cell binding assays is used. A B-cell line with the high expression of CD20 is used. Cold receptor-F_v fusion protein is allowed to bind for 40 minutes on ice. Cells are washed twice and ¹²⁵I-IL-15 are added. IL-15 labeled by the Iodogen method to specific activities of up to 70 μ Ci/ μ g is added at 1 nM in the presence of a 200-fold molar excess of cold IL-15 and cold IL-2 as a negative control (IL-2 does not bind to IL-15R α). After another 40 minutes on ice, the cells are spun through an oil cushion and counted as above.

Example 6. Assay of ability of sIL-15R α -1F5scF_v fusion protein to internalize CD20

The fusion protein and parental 1F5 are labeled in parallel with ¹²⁵I. The CD20+ cell line, RL, is used. Binding is carried out on ice at 5 nM for both labels on equal aliquots of cells. Cold IL-15 or cold IL-2 is added to some tubes to assess the effects on internalization. Unbound labels are removed by pelleting and washing the cells. A t₀ value is determined and the remaining aliquots are placed at 37°C and removed at various time intervals. Catabolized and released ¹²⁵I is distinguished from dissociated, intact protein label by precipitation with 10% TCA. If enhanced internalization occurs when cold IL-15 is added to labeled fusion protein and not to controls, a reverse experiment using labeled IL-15 and unlabeled fusion protein is done to approximate the *in vivo* situation.

In vitro studies using the residualizing labels ^{88}Y , ^{111}In , ^{125}I -dilactitol-tyramine also are done. These agents better represent the behavior of the radionuclides to be tested for therapy, namely, ^{90}Y and ^{131}I on a residualizing label. For Y and In radiometals IL-15 is reacted with isothiocyanatobenzyl-DTPA and then tested for retention of bindability in a cold ligand inhibition assay as described above, following protocols for chelate labeling. Briefly, rIL-15 is dialyzed against 0.1 M Hepes, pH=8.2. To this is added a 6-fold molar excess of isothiocyanatobenzyl-DTPA. The reaction is carried out for 2 hours at room temperature. Labeled IL-15 is separated from unbound chelate by gel filtration on a PD-10 column. If adequate bioactivity is retained, the chelated IL-15 is dialyzed into 0.1 M sodium acetate, pH=6.0 under metal-free conditions in preparation for loading with radiometal.

Example 7. Construction of a IL-15/onconase immunotoxin

A fusion protein consisting of IL-15 and onconase is genetically engineered following procedures outlined by Rybak (1995) for the production of mAb-onconase fusion proteins. Briefly, a sequence-confirmed fragment corresponding to the mature IL-15 protein is ligated to the sequence of onconase with the IL-15 sequence lying 5', though the other orientation also can be evaluated. Onconase genes are cloned from two or more frog species. Authentic fragments representing the fusion sequence are subcloned into the pET21d vector again using a C-terminal hexahistidine tag. The complete sequence encoding the entire IL-15-onconase fusion protein is confirmed in the pET vector in the XL1Blue strain as above. Appropriate clones are expanded to produce plasmid for transformation of the AD494 (DE3) *E. coli* expression strain.

Transformed clones are picked and grown in small scale culture, induced with IPTG, lysed in SDS sample buffer and run out on a SDS-PAGE gel for Coomassie staining and transblotting for detection both with anti-IL15 antibodies and anti-onconase antibodies. Isolation and washing of inclusion bodies, their solubilization, renaturation and subsequent purification are performed using the steps outlined above. The final product is tested for its ability to bind the IL-15

receptor by labeling with ^{125}I and comparing it with equimolar concentrations of similarly labeled IL-15 in the cell binding assay described above.

Conjugates that retains bindability are tested for cytotoxicity on cell lines known to express receptors for IL-15, such as HuT 102B2 or MLA144. A ^3H -leucine incorporation assay is performed in which 1×10^4 HuT 102B2 or
5 MLA144 cells are plated in duplicate wells in a 96-well plate and cultured in the presence or absence of IL-2, IL-15, IL-15-onconase and media alone for 30 hours, at which point label is added.

Specificity is checked by adding IL-2 or IL-15 together with the fusion
10 protein to look for inhibition of cytotoxicity. IL-15 should efficiently inhibit, while IL-2 should inhibit only partially. After a 6 hour incorporation period, proteins are harvested onto a type B glass fiber filter mat and counted in a MicroBeta scintillation counter (Wallac, Gaithersburg, MD).

The assay is repeated for cytotoxic fusion protein with a model NHL cell
15 line such as RL. In this case the assay is carried out in the presence and absence of the sIL-15R α -1F5scF $_v$ fusion protein to determine toxicity and the ability to bind and internalize greater amounts of the immunotoxin. A dose response curve for each experimental and control condition is generated. To control for nonspecific toxicity a CD20- cell line is used. Inhibition of toxicity by the
20 addition of excess unlabeled 1F5 mAb, IL-15 and IL-2 also is tested.

Example 8. Antibody-onconase conjugates

In order to assess the cytotoxic activity of onconase-based immunotoxins on B lymphoma cell lines, LL2-onconase conjugates were prepared, and their effects tested on Daudi, B-lymphoma cell line. Both whole IgG and Fab' conjugates were prepared and were found to inhibit this cell line in the
25 subnanomolar range. Furthermore, the effect was shown to be dependent on the CD22 reactivity of the conjugate since inhibitory effects were nearly eliminated by excess cold antibody.

In another series of experiments different permutations of conjugates
30 between three mAbs (LL1 [class II invariant chain], LL2 and 5E9[anti-transferrin receptor]) and two RNase superfamily toxins (onconase and EDN) were tested on

a panel of cell lines that included three B-lymphoma cell lines (Daudi, Raji, CA-46), MDA-MB-231, a breast cancer line, and HuT 102, a human T cell line. Dose response curves were done with the readout being protein synthesis as assessed by ^3H -leucine incorporation. Cells were plated in the presence of an absence of mAb, toxin or conjugate, cultured for 16 hours and then pulsed with 1 μCi /well of label. Incorporation was measured by harvesting the cells onto a type B glass fiber filter, followed by scintillation counting. As shown in Table 2, LL2-onconase had the lowest IC_{50} values of all the conjugates tested.

TABLE 2

Cytotoxicity of Onconase and EDN conjugates vs. Component Proteins

 $\text{IC}_{50}(\text{pM})$

Cell line	LL2-Onc	LL1-Onc	Onc	LL2	LL2-EDN	5E9-EDN	EDN
Daudi	800		>200,000	>23000	>43000		
CA-46	800	2300	>200,000	>23000	>43000		
Raji	800		>200,000	>23000			
Hut-102	>40,000		37,000				
MDA-MB-0231						1600	>7,000,000

Example 9. Therapy of B-CLL

A patient having B-CLL is infused intravenously with a sterile, pyrogen-free solution containing a target dose of sIL-15R α -1F5scF $_v$ fusion protein labeled with I^{123} in phosphate-buffered saline (PBS), prepared according to Examples 3 and 4. After the fusion protein has bound to malignant B cells and has substantially cleared from the circulation of the patient, as monitored by gamma camera imaging, the patient then is infused intravenously with a sterile, pyrogen-free PBS solution that contains a therapeutic dose of IL-15/onconase immunotoxin conjugate, prepared according to Example 7. Subsequent radioimmunodetection, with labeled anti-CD20 shows significant reduction in the lymphoma.

What Is Claimed Is:

1. A conjugate of a non-immunogenic toxin or therapeutic radionuclide and a cell-specific cytokine.
2. A conjugate as claimed in claim 1, wherein said toxin is an RNase.
3. A conjugate as claimed in claim 1, wherein said cytokine is IL-15.
4. A conjugate as claimed in claim 3, wherein said toxin is onconase.
5. A conjugate as claimed in claim 4, which additionally comprises a diagnostic radionuclide.
6. A composition comprising a conjugate according to claim 1, and a pharmaceutically acceptable carrier.
7. A composition as claimed in claim 6, additionally comprising a diagnostic radionuclide conjugated to said cytokine.
8. A fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α .
9. A fusion protein as claimed in claim 8, wherein said bispecific antibody is a scF_v.
10. A fusion protein as claimed in claim 9, wherein said scF_v is a fusion of two individual scF_v molecules.
11. A fusion protein as claimed in claim 8, wherein said cell marker is a B-cell restricted antigen.

12. A fusion protein as claimed in claim 11, wherein said cell marker is CD20.

13. A fusion protein as claimed in claim 8, wherein said region of IL-15 α is an extracellular domain of IL-15 α .

14. A composition comprising a fusion protein according to claim 8 and a pharmaceutically acceptable carrier.

15. A kit comprising a conjugate of onconase and IL-15, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α .

16. A method of treating a malignancy, comprising the steps of:
first administering to a subject having a malignancy a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , and then administering to said subject therapeutically effective amount of a conjugate of onconase and IL-15.

17. A method as claimed in claim 16, additionally comprising a step of administering at least one of chemotherapy and radiation therapy in an amount sufficient to prevent tumor cells from activating DNA-repair mechanisms.

18. A method as claimed in claim 16, wherein said cell marker is a B-cell restricted antigen and said subject has a B-cell malignancy.

19. A method as claimed in claim 18, wherein said cell marker is CD20 and said subject has B-cell lymphocytic leukemia, non-Hodgkin's lymphoma, hairy cell leukemia or acute myelogenous leukemia.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/17924

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K47/48 A61K51/08 C07K19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 00762 A (AKZO NV) 23 January 1992 see examples see claims ---	1,6
X	WO 94 07535 A (MALLINCKRODT MEDICAL, INC.) 14 April 1994 see examples see claims ---	1,6,7
X	WO 93 23062 A (IMMUNOMEDICS INC.) 25 November 1993 see claims 1,2,9 ---	1,6
A	WO 96 26274 A (IMMUNEX CORP.) 29 August 1996 see examples see claims --- -/--	1-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

17 February 1998

Date of mailing of the international search report

17. 03. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/17924

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 30695 A (IMMUNEX CORP.) 16 November 1995 see examples see claims	1-19
A	--- D. ANDERSON ET AL.: "Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 50, 15 December 1995, BALTIMORE, MD, USA, pages 29862-29869, XP002056003 see abstract	1-19
A	--- J. DE JONG ET AL.: "Interaction of IL-15 with the shared IL-2 receptor beta and gamma-c subunits." THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 4, 15 February 1996, BALTIMORE, MD, USA, pages 1339-1348, XP002056004 see abstract	1-19
A	--- D. CHAE ET AL.: "Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression." THE JOURNAL OF IMMUNOLOGY, vol. 157, no. 7, 1 October 1996, BALTIMORE, MD, USA, pages 2813-2819, XP002056005 see abstract see figure 1 -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 17924

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-19
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 16-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/US 97/17924

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9200762 A	23-01-92	AU 657910 B AU 8060691 A CA 2086679 A EP 0537229 A	30-03-95 04-02-92 06-01-92 21-04-93
WO 9407535 A	14-04-94	US 5346686 A AU 5353194 A CA 2146239 A EP 0670736 A JP 8511765 T US 5605671 A	13-09-94 26-04-94 14-04-94 13-09-95 10-12-96 25-02-97
WO 9323062 A	25-11-93	US 5541297 A CA 2118032 A EP 0651646 A JP 8500084 T US 5601825 A	30-07-96 25-11-93 10-05-95 09-01-96 11-02-97
WO 9626274 A	29-08-96	AU 5027596 A CA 2210491 A EP 0811065 A FI 973361 A NO 973705 A	11-09-96 29-08-96 10-12-97 15-10-97 22-10-97
WO 9530695 A	16-11-95	US 5591630 A AU 2434495 A CA 2188279 A EP 0759942 A	07-01-97 29-11-95 16-11-95 05-03-97